Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11896246 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1EPHX2FAAHCNR1 | |
| SCHEMBL10961339 | 0.92 | L3MBTL1 (0.53) | L3MBTL1TDP1EPHX2TSHRHRH4 | |
| SCHEMBL20561263 | 0.92 | L3MBTL1 (0.53) | L3MBTL1TDP1EPHX2TSHRHRH4 | |
| SCHEMBL9197227 | 0.90 | TDP1 (0.50) | L3MBTL1TDP1EPHX2FAAHCNR1 | |
| SCHEMBL14496882 | 0.90 | TDP1 (0.50) | L3MBTL1TDP1EPHX2FAAHCNR1 | |
| SCHEMBL9197255 | 0.90 | TDP1 (0.50) | L3MBTL1TDP1EPHX2FAAHCNR1 | |
| SCHEMBL14496883 | 0.90 | TDP1 (0.50) | L3MBTL1TDP1EPHX2FAAHCNR1 | |
| SCHEMBL16878885 | 0.86 | TSHR (0.50) | L3MBTL1TDP1EPHX2FAAHCNR1 | |
| SCHEMBL15869130 | 0.86 | TSHR (0.50) | L3MBTL1TDP1EPHX2FAAHCNR1 | |
| SCHEMBL16878886 | 0.86 | TSHR (0.50) | L3MBTL1TDP1EPHX2FAAHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2487149-A1 | METHOD FOR PRODUCING KETONE | JX Nippon Oil & Energy Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120197036-A1 | METHOD FOR MANUFACTURING KETONE | OSAKA UNIVERSITY (JP) | 2012-08-02 | — | — | US | disclosed |
| CN-102548942-A | Method for producing ketone | JX NIPPON OIL & ENERGY CORP | 2012-07-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197036-A1 | METHOD FOR MANUFACTURING KETONE | CBR1, CBR3, DUOX1 | L3MBTL1 1576/4885TDP1 3122/4885EPHX2 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.